Hasil Pencarian - David E. Gerber

Perbaiki Hasil
  1. 1
    Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report

    Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report oleh Amrit S. Gonugunta, Mitchell S. von Itzstein, David E. Gerber

    Diterbitkan 2022-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Upfront Brain Treatments Followed by Lung Surgery Improves Survival for Stage IV Non-small Cell Lung Cancer Patients With Brain Metastases: A Large Cohort Analysis

    Upfront Brain Treatments Followed by Lung Surgery Improves Survival for Stage IV Non-small Cell Lung Cancer Patients With Brain Metastases: A Large Cohort Analysis oleh Xiaopeng He, Xiaopeng He, Shen Yin, Shen Yin, Hongyu Liu, Rong Lu, Kemp Kernstine, David E. Gerber, David E. Gerber, David E. Gerber, Yang Xie, Yang Xie, Yang Xie, Donghan M. Yang

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Placing a Cancer Diagnosis in Clinical Context: Applying Functional Trajectories to Advanced NSCLC

    Placing a Cancer Diagnosis in Clinical Context: Applying Functional Trajectories to Advanced NSCLC oleh Heidi A. Hamann, PhD, David E. Gerber, MD

    Diterbitkan 2022-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Do mRNA profiles of lung adenocarcinomas provide information that will help individual patients?

    Do mRNA profiles of lung adenocarcinomas provide information that will help individual patients? oleh Mitchell S. von Itzstein, David E. Gerber, John D. Minna

    Diterbitkan 2020-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    How have we diagnosed early-stage lung cancer without radiographic screening? A contemporary single-center experience.

    How have we diagnosed early-stage lung cancer without radiographic screening? A contemporary single-center experience. oleh Evelyn O Taiwo, Jeffrey T Yorio, Jingsheng Yan, David E Gerber

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Acknowledging and addressing real-world challenges to treating immune-related adverse events

    Acknowledging and addressing real-world challenges to treating immune-related adverse events oleh Bonnie L Bermas, Mitchell S von Itzstein, David E Gerber, Alexa Meara

    Diterbitkan 2024-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Systemic and Intracranial Efficacy of Osimertinib in EGFR L747P-Mutant NSCLC: Case Report

    Systemic and Intracranial Efficacy of Osimertinib in EGFR L747P-Mutant NSCLC: Case Report oleh David E. Gerber, MD, Melissa Mayer, RN, Jeffrey Gagan, MD, Mitchell S. von Itzstein, MD

    Diterbitkan 2022-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care quality?

    Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care qualit... oleh Mitchell S von Itzstein, Arjun Gupta, Kemp H Kernstine, Kristin C Mara, Sahil Khanna, David E Gerber

    Diterbitkan 2020-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Thirteen-Year Survival in a Patient With Diffuse Bilateral Lepidic-Predominant Adenocarcinoma: A Case Report of Lung Transplantation and Local Salvage

    Thirteen-Year Survival in a Patient With Diffuse Bilateral Lepidic-Predominant Adenocarcinoma: A Case Report of Lung Transplantation and Local Salvage oleh Elizabeth R. Zhang-Velten, MD, PhD, David E. Gerber, MD, Kenneth D. Westover, MD, PhD

    Diterbitkan 2020-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Closing the gap: Contribution of surgical best practices to outcome differences between high‐ and low‐volume centers for lung cancer resection

    Closing the gap: Contribution of surgical best practices to outcome differences between high‐ and low‐volume centers for lung cancer resection oleh Mitchell S. vonItzstein, Rong Lu, Kemp H. Kernstine, Ethan A. Halm, Shidan Wang, Yang Xie, David E. Gerber

    Diterbitkan 2020-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice

    Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice oleh Mitchell S. von Itzstein, Mitchell S. von Itzstein, Yuqiu Yang, Yiqing Wang, David Hsiehchen, Thomas Y. Sheffield, Farjana Fattah, Vinita Popat, Murtaza Ahmed, Jade Homsi, Jade Homsi, Jonathan E. Dowell, Jonathan E. Dowell, Sawsan Rashdan, Sawsan Rashdan, Jay Lohrey, Jay Lohrey, Hans J. Hammers, Hans J. Hammers, Randall S. Hughes, Randall S. Hughes, Tao Wang, Tao Wang, Yang Xie, Yang Xie, David E. Gerber, David E. Gerber, David E. Gerber

    Diterbitkan 2024-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Distinct NSCLC EGFR Variants in a Family With Li-Fraumeni Syndrome: Case Report

    Distinct NSCLC EGFR Variants in a Family With Li-Fraumeni Syndrome: Case Report oleh Shelby Edmondson, BA, Mitchell S. von Itzstein, MD, Brian Reys, MS, Melissa Mayer, BA, Jeffrey Gagan, MD, David E. Gerber, MD

    Diterbitkan 2022-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden

    DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden oleh David Hsiehchen, Antony Hsieh, Robert M. Samstein, Tianshi Lu, Muhammad S. Beg, David E. Gerber, Tao Wang, Luc G.T. Morris, Hao Zhu

    Diterbitkan 2020-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer

    Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer oleh Shetal A. Patel, David E. Gerber, Allison Deal, Kathe Douglas, Chad V. Pecot, Carrie Lee, Joan Schiller, Nirav Dhruva, Jared Weiss

    Diterbitkan 2021-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial

    Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial oleh Caitlin C. Murphy, Hannah M. Fullington, David E. Gerber, Isaac Alex Bowman, Maneka Puligandla, Janice P. Dutcher, Robert S. DiPaola, Naomi B. Haas

    Diterbitkan 2021-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Survival of patients newly diagnosed with colorectal cancer and with a history of previous cancer

    Survival of patients newly diagnosed with colorectal cancer and with a history of previous cancer oleh Sandi L. Pruitt, David E. Gerber, Hong Zhu, Daniel F. Heitjan, Bhumika Maddineni, Danyi Xiong, Amit G. Singal, Anna Tavakkoli, Ethan A. Halm, Caitlin C. Murphy

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Distinct autoantibody profiles across checkpoint inhibitor types and toxicities

    Distinct autoantibody profiles across checkpoint inhibitor types and toxicities oleh Hong Mu-Mosley, Mitchell S. von Itzstein, Farjana Fattah, Jialiang Liu, Chengsong Zhu, Yang Xie, Edward K. Wakeland, Jason Y. Park, Brad S. Kahl, Catherine S. Diefenbach, David E. Gerber

    Diterbitkan 2024-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids

    Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids oleh Ke Gong, Gao Guo, Nicole A. Beckley, Xiaoyao Yang, Yue Zhang, David E. Gerber, John D. Minna, Sandeep Burma, Dawen Zhao, Esra A. Akbay, Amyn A. Habib

    Diterbitkan 2021-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Use of artificial intelligence chatbots in clinical management of immune-related adverse events

    Use of artificial intelligence chatbots in clinical management of immune-related adverse events oleh Jarushka Naidoo, Igor Puzanov, Paolo A Ascierto, Marc S Ernstoff, Douglas B Johnson, Fei Ye, Mitchell S von Itzstein, David E Gerber, Benjamin Switzer, Aliyah Pabani, Hannah Burnette, Run Fan

    Diterbitkan 2024-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    Association between immune-related adverse event timing and treatment outcomes

    Association between immune-related adverse event timing and treatment outcomes oleh David Hsiehchen, Abdul Rafeh Naqash, Magdalena Espinoza, Mitchell S. Von Itzstein, Alessio Cortellini, Biagio Ricciuti, Dwight H. Owen, Mehak Laharwal, Yukihiro Toi, Michael Burke, Yang Xie, David E. Gerber

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: